Andreas Burchert

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 611 citations · Full text

Medicine, Oncology, Pharmacology +11

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i>–Internal Tandem Duplication Mutation (SORMAIN)

Andreas Burchert, Gesine Bug, Lea Fritz et al. · Journal of Clinical Oncology · 2020 · 551 citations · Full text

Medicine, Hematology, Oncology +15

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Robert Zeiser, Andreas Burchert, Claudia Lengerke et al. · Leukemia · 2015 · 540 citations · Full text

Medicine, Clinical Sciences, Immunology +16

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 400 citations · Full text

Medicine, Hematology, Oncology +6

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Nicolaus Kröger, Ernst Holler, Guido Kobbe et al. · Blood · 2009 · 394 citations · Full text

Medicine, Hematology, Immunology +17